All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality
Clinical Kidney Journal · 04.01.2024 · 17 (1)
DOI: 10.1093/ckj/sfad292 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Kidney Journal, online erschienen am 28.11.2023. Verfasst von Jia-Jin Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Research Center, Nephrology Department, Chang Gung Memorial Hospital in Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have been associated with acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been systematically examined. Additionally, exposure to proton pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs) were considered as risk factors for AKI, but with inconclusive results in ICI-related AKI. Our aim was to analyse the occurrence rate of all-cause AKI and ICI-related AKI and the occurrence rates of severe AKI and dialysis-requiring AKI, and to determine whether exposure to PPIs and NSAIDs poses a risk for all-cause and ICI-related AKI.
Methods
This study population was adult ICI recipients. A systematic review was conducted by searching MEDLINE, Embase and PubMed through October 2023. We included prospective trials and observational studies that reported any of the following outcomes: the occurrence rate of all-cause or ICI-related AKI, the relationship between PPI or NSAID exposure and AKI development or the mortality rate in the AKI or non-AKI group. Proportional meta-analysis and pairwise meta-analysis were performed. The evidence certainty was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework.
Results
A total of 120 studies comprising 46 417 patients were included. The occurrence rates of all-cause AKI were 7.4% (14.6% from retrospective studies and 1.2% from prospective clinical trials). The occurrence rate of ICI-related AKI was 3.2%. The use of PPIs was associated with an odds ratio (OR) of 1.77 [95% confidence interval (CI) 1.43–2.18] for all-cause AKI and an OR of 2.42 (95% CI 1.96–2.97) for ICI-related AKI. The use of NSAIDs was associated with an OR of 1.77 (95% CI 1.10–2.83) for all-cause AKI and an OR of 2.57 (95% CI 1.68–3.93) for ICI-related AKI.
Conclusions
Our analysis revealed that approximately 1 in 13 adult ICI recipients may experience all-cause AKI, while 1 in 33 adult ICI recipients may experience ICI-related AKI. Exposure to PPIs and NSAIDs was associated with an increased OR risk for AKI in the current meta-analysis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kidney Research Center, Nephrology Department, Chang Gung Memorial Hospital in Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
- Nephrology Department, Chansn Hospital, Taoyuan City, Taiwan.
- Department of Hematology and Oncology, Chang Gung Memorial Hospital in Linkou and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- School of Medicine, College of Medicine, Chang Gung University; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
- Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
ORCID-Profile: Tao-Han Lee, George Kuo, Cheng-Chia Lee, Chih-Hsiang Chang, Yu-Kang Tu
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Chen, J. J., Lee, T. H., Kuo, G., Yen, C. L., Lee, C. C., Chang, C. H., Tu, K. H., Chen, Y. C., Fang, J. T., Hung, C. C., Yang, C. W., Chou, W. C., Chi, C. C., Tu, Y. K., & Yu Yang, H. (2024). All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. Clinical Kidney Journal, 17(1). https://doi.org/10.1093/ckj/sfad292
Vancouver
Chen JJ, Lee TH, Kuo G, Yen CL, Lee CC, Chang CH, et al. All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. Clinical Kidney Journal. 2024;17(1). doi:10.1093/ckj/sfad292
BibTeX
@article{Chen2024,
author = {Chen, Jia-Jin and Lee, Tao-Han and Kuo, George and Yen, Chieh-Li and Lee, Cheng-Chia and Chang, Chih-Hsiang and Tu, Kun-Hua and Chen, Yung-Chang and Fang, Ji-Tseng and Hung, Cheng-Chieh and Yang, Chih-Wei and Chou, Wen-Chi and Chi, Ching-Chi and Tu, Yu-Kang and Yu Yang, Huang-},
title = {All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {1},
doi = {10.1093/ckj/sfad292}
}
EUVIMED